Commentary

Video

Data for Navtemadlin in Relapsed/Refractory Myelofibrosis

Author(s):

Sangeetha Venugopal, MD, MS

Sangeetha Venugopal, MD, MS, discusses data from the BOREAS trial for navtemadlin in relapsed/refractory myelofibrosis.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Raajit Rampal, MD, director of the Center for Hematologic Malignancies and director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center
6369343864112
Dr Kishtagari on Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Al Malki
Dr Sekkeres on the Association Between Smoking and Disease Progression in MDS
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the potential for the use of oral HMAs in MDS.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the implications of the FDA approval of imetelstat for transfusion-dependent anemia in MDS.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss other potential roles for luspatercept in MDS and beyond.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss long-term transfusion independence data for luspatercept in MDS.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the importance of treating anemia in myelodysplastic syndrome.
Related Content
Glioblastoma |Image Credit: © Sebastian Kaulitzki - stock.adobe.com
March 18th 2025

Viral Mimicry May Enhance Immune Response Against Glioblastomas

Samuel A. Kareff, MD, MPH, outgoing chief fellow, hematology and medical oncology, University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital
October 21st 2024

Phase 1 Trials Provide Oncology Fellows With Valuable Clinical Research Experience: With Samuel A. Kareff, MD, MPH

The top 5 OncLive videos of the week cover insights in TGCT, NSCLC, TNBC, AML, and MDS.
March 9th 2025

Five Under 5: Top Oncology Videos for the Week of 3/2

Mikkael A. Sekeres, MD, professor, medicine, chief, Division of Hematology, Leukemia Section, University of Miami Sylvester Comprehensive Cancer Center
July 1st 2024

FDA Approval Insights: Imetelstat in Lower-Risk MDS and Transfusion-Dependent Anemia

Juan P. Alderuccio, MD of Sylvester Cancer Center
March 5th 2025

Sylvester Study Leads to Updated National Guidelines for Follicular Lymphoma Treatment

Ivosidenib/CPX-351 in IDH1-Mutated AML and MDS | Image credit: © Maris – stock.adobe.com
March 4th 2025

Ivosidenib/CPX-351 Shows Early Activity and Is Safe in IDH1-Mutated R/R AML, High-Risk MDS